Geneseq Biosciences is a Melbourne based biotechnology company.
We are pioneering the development of new “liquid biopsy” tests to help doctors individualise cancer diagnostics & treatment options.
Our first test, Melaseq, is designed to accurately detect the genomic (microRNA) fingerprint of active melanoma in blood.
Melanoma is the most deadly form of skin cancer and is 3-4 more prevalent in Australia compared to the US and the UK. Early detection is the best defence against this aggressive form of cancer, however current methods are subjective, costly and can be inaccurate.
Our goal is to provide physicians with a new precision-medicine tool to help them diagnose melanoma in its early and most treatable stage. We believe Melaseq will also reduce the number of unnecessary, invasive biopsies and dramatically improve healthcare resource utilisation.